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Abstract
Background: With the rapid expansion of antiretroviral therapy (ART) services in sub-Saharan Africa there is growing
recognition of the importance of fertility and childbearing among HIV-infected women. However there are few data on
whether ART initiation influences pregnancy rates.
Methods and Findings: We analyzed data from the Mother-to-Child Transmission-Plus (MTCT-Plus) Initiative, a multicountry
HIV care and treatment program for women, children, and families. From 11 programs in seven African countries, women
were enrolled into care regardless of HIV disease stage and followed at regular intervals; ART was initiated according to
national guidelines on the basis of immunological and/or clinical criteria. Standardized forms were used to collect
sociodemographic and clinical data, including incident pregnancies. Overall 589 incident pregnancies were observed
among the 4,531 women included in this analysis (pregnancy incidence, 7.8/100 person-years [PY]). The rate of new
pregnancies was significantly higher among women receiving ART (9.0/100 PY) compared to women not on ART (6.5/100
PY) (adjusted hazard ratio, 1.74; 95% confidence interval, 1.19–2.54). Other factors independently associated with increased
risk of incident pregnancy included younger age, lower educational attainment, being married or cohabiting, having a male
partner enrolled into the program, failure to use nonbarrier contraception, and higher CD4 cell counts.
Conclusions: ART use is associated with significantly higher pregnancy rates among HIV-infected women in sub-Saharan
Africa. While the possible behavioral or biomedical mechanisms that may underlie this association require further
investigation, these data highlight the importance of pregnancy planning and management as a critical but neglected
component of HIV care and treatment services.
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By the end of 2007 there were almost 3,000,000 HIV-infected
individuals receiving antiretroviral therapy (ART) in resource-
limited settings [1]. The global roll-out of ART has contributed to
a greater awareness of issues related to fertility and childbearing
among HIV-infected women and men [2,3], particularly in sub-
Saharan Africa where a large proportion of HIV-infected
individuals are women in their reproductive years and the
prevention of mother-to-child transmission (PMTCT) of HIV is
an ongoing challenge [1,4].
Studies from Europe and North America indicate that HIV-
infected women frequently become pregnant [5,6], and most HIV-
infected individuals have fertility desires that change over time [7].
Data are sparse from Africa however, where socioeconomic and
cultural imperatives have a substantial impact on female fertility
[8]. Small qualitative studies from Africa suggest that HIV might
modify but does not eliminate broader desires to have children
[9,10] and that ART use may be associated with increased fertility
desires among HIV-infected women, possibly through increased
hopes and planning for the future [11].
HIV care and treatment services are in a unique position to
address the childbearing desires of HIV-infected individuals as well
as to ensure safe pregnancy and delivery [12]. These services have
the opportunity to prevent unwanted pregnancies through
provision of effective contraception [13], taking into account
potential interactions between antiretroviral drugs and hormonal
contraceptives. HIV care and treatment services can also optimize
ART for women before conception and during pregnancy to
decrease the risk of vertical transmission of HIV and to avoid the
use of potentially teratogenic drugs [4] thus ensuring optimal
outcomes in these women and their children [14,15].
Despite the importance of fertility and childbearing in HIV-
infected individuals, little is known about whether initiation of
ART alters pregnancy rates among women in HIV care and
treatment programs in resource-limited settings. One study from
the United States suggested that ART use did not impact
pregnancy rates [5], but there are no data from sub-Saharan
Africa. We examined the incidence of pregnancy before and after
ART initiation in women enrolled in a multicountry HIV care and
treatment program in Africa.
Methods
The MTCT-Plus Initiative
Data for this analysis come from the MTCT-Plus Initiative, a
multicountry HIV care and treatment program that utilizes a
woman-centered, family-focused service model. The design and
progress of the Initiative has been previously described (www.
mtctplus.org) [16,17]. At each site, pregnant or recently postpar-
tum HIV-infected women receiving PMTCT services were
enrolled into HIV care and treatment services irrespective of
HIV disease stage (‘‘index women’’). Infected children, partners,
and other family members were also offered enrollment. Services
were initiated during 2003 and 2004.
HIV Care and Treatment Services
All enrolled women received a package of HIV primary care
services including regular clinical assessments and CD4 cell counts
every 6 mo. Barrier and nonbarrier contraceptive methods were
provided, either on-site or by referral, with specific methods based
on local availability. There was no standardized counseling on
pregnancy and contraceptive use across sites, although all sites
provided counseling and psychosocial support services regarding
HIV-related stigma, disclosure, and treatment adherence.
ART initiation was based on national or World Health
Organization (WHO) guidelines [18]. Typically this entailed
ART initiation for patients with WHO stage 4 disease, CD4 cell
counts #200 cells/ml, or WHO stage 3 and CD4 cell counts #350
cells/ml. First-line regimens involved two nucleoside reverse
transcriptase inhibitors and a non-nucleoside reverse transcriptase
inhibitor (primarily nevirapine). The follow-up schedule at each
site was quarterly to semi-annually for individuals not receiving
ART (‘‘pre-ART’’) and monthly for individuals receiving ART
(‘‘on-ART’’).
Measurements
Upon enrollment women completed a short, standardized
provider-administered questionnaire, which included demograph-
ic and socioeconomic information, partnership status, and
obstetric history. At enrollment and each follow-up visit, clinicians
completed a standardized medical survey including history of
opportunistic infections, WHO stage, initiation or continuing use
of ART, contraceptive use (including the use of specific barrier and
nonbarrier methods), and pregnancy status (including pregnancy
loss since the previous visit). The gestational age of pregnancies at
detection was estimated clinically (on the basis of dates of last
menstrual period or symphysis-fundal palpation), and estimated
delivery dates were calculated accordingly. CD4 cell enumeration
was conducted at local laboratories.
Ethical Approval
The conduct of the MTCT-Plus Initiative as a service delivery
program with data collection for monitoring and evaluation
purposes was approved by the Institutional Review Board of
Columbia University.
Data Analysis
Data were analyzed using Stata version 10.0 (Stata Corpora-
tion). Timing of incident pregnancies was based on estimated
conception dates, calculated 280 d before the date of delivery
(estimated or observed). Pregnancy-free survival was calculated
from 60 d following the delivery of the index pregnancy (during or
after which women were enrolled into the program) until either:
incident pregnancy, death, loss to follow-up, or censoring at the
last clinical visit recorded before 31 January 2007. Participants
were censored after their first new pregnancy during follow-up.
Women who reported being sterilized or having a hysterectomy
were excluded. Follow-up of women prior to initiation of ART was
designated as the ‘‘pre-ART period,’’ while follow-up after
initiation of ART is referred to as the ‘‘on-ART’’ period.
Median values were compared using the rank-sum test and
proportions were compared using chi-square tests replaced by
Fisher’s exact test for sparse data. Pregnancy rates were calculated
with 95% confidence intervals (CIs), and crude rates were
compared as incident pregnancy rate ratios (RRs). The time to
pregnancy was compared between subgroups using proportional
hazards models with the Breslow method for tie handling. The
results of these models are expressed as hazard ratios (HRs) with
95% CI. In these models, the clustering of women within sites was
accounted for using the sandwich-Huber-White robust variance
estimation method [19]. Parameters of interest that varied during
the course of follow-up (including ART use, contraceptive use,
current CD4 cell count, and enrollment of a male partner into the
program) were analyzed as time-dependent covariates. On the
basis of the final model we plotted the pregnancy-free survival
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adjusted for relevant covariates. To assess the changing rate of
pregnancy over time for women during the pre-ART and on-ART
periods, the instantaneous hazard of pregnancy from proportional
hazards models was graphed with corresponding 95% CI using a
smoothing function. All statistical tests are two-sided at a=0.05.
Results
Baseline Characteristics
A total of 4,531 women enrolled at 11 sites between February
2003 and January 2007 were eligible for analysis. The median
number of women enrolled per site was 410 (range, 211–666).
Table 1 describes the cohort overall and by age group. The
median age was 27 y (interquartile range (IQR), 24–31 y). The
median parity was 2 (including the index pregnancy; IQR, 1–3);
this increased with age, and overall 22% of women were
primiparous during follow-up. The median CD4 cell count at
enrollment was 366 cells/ml (IQR, 208–562). At the first follow-up
visit, 39% of women (n=1,755) reported contraceptive use,
including barrier methods (17% reported condom use, n=752),
injectable hormonal methods (15%, n=664), oral hormonal
contraceptives (4%, n=160), intrauterine device (IUD) use (1%,
n=31), or other methods (3%, n=148). 259 women (6%) reported
using condoms as well as a nonbarrier method.
Approximately half of the women (56%, n=2,551) were
observed only during the pre-ART period; 580 women (13%)
were observed only on-ART, and another 1,400 (31%) were
observed both pre-ART and on-ART.
Incidence of Pregnancy during Follow-up
The median duration of follow-up was 482 d during pre-ART
and 696 d on-ART. Overall, there were 7,565 person-years of
observation following the index pregnancy and 589 incident
pregnancies were detected (incidence rate, 7.79 per 100 person-
years; 95% CI 7.18–8.43). This total was comprised of 244
incident pregnancies over 3,747 person-years of observation
during the pre-ART period (rate, 6.51 per 100 person-years;
Table 1. Description of sociodemographic and clinical characteristics of the cohort of women enrolled into MTCT-Plus and eligible
for incident pregnancy analysis, overall and by age category.
Characteristics
All Participants









Median years of schooling (y) 99 9 9 8
Years (y) of education
0–3 602 (13) 170 (12) 199 (13) 153 (14) 80 (17)
4–7 1,170 (26) 348 (25) 369 (23) 297 (27) 156 (33)
8–11 1,644 (36) 572 (42) 553 (35) 362 (33) 157 (32)
12+ 1,109 (25) 283 (21) 453 (29) 282 (26) 91 (19)
Employed 1,045 (23) 195 (14) 387 (25) 315 (29) 148 (31)
Household electricity 2,721 (60) 726 (54) 1,028 (65) 680 (63) 278 (58)
Household piped water 1,919 (43) 535 (39) 715 (46) 466 (43) 203 (42)
Currently married/cohabiting 2,929 (66) 821 (61) 1,044 (67) 741 (68) 323 (70)
Male partner enrolled into the program 1,010 (22) 306 (22) 368 (23) 246 (22) 90 (19)
Parity: median 22 2 3 4
Primiparous 1,013 (22) 613 (45) 307 (20) 88 (8) 11 (2)
Estimated travel time to facility (min)
,30 1,623 (36) 511 (37) 565 (36) 375 (34) 172 (36)
30–60 2,169 (48) 680 (50) 736 (47) 544 (50) 209 (43)
60+ 725 (16) 179 (13) 271 (17) 172 (16) 103 (21)
WHO stage at enrollment
1 2,911 (64) 966 (70) 1012 (64) 641 (59) 292 (60)
2 911 (20) 262 (19) 320 (20) 241 (22) 88 (18)
3 624 (14) 127 (9) 212 (13) 196 (18) 89 (18)
4 76 (2) 17 (1) 29 (2) 15 (1) 15 (3)
Median CD4 at enrollment (cells/ml) 366 442 353 322 319
$500 1,709 (38) 649 (47) 568 (36) 328 (30) 158 (33)
350–499 863 (19) 278 (20) 295 (19) 207 (19) 83 (17)
20–349 984 (22) 256 (19) 360 (23) 260 (24) 108 (22)
,200 975 (22) 190 (14) 351 (22) 299 (27) 135 (28)
Initiated ART during follow-up 1,978 (44) 461 (34) 712 (45) 550 (50) 255 (53)
doi:10.1371/journal.pmed.1000229.t001
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person-years of observation during the on-ART period (rate, 9.03
per 100 person-years; 95% CI 8.13–10.03).
Crude rates of incident pregnancy varied by site and country,
with rates ranging from 3.29 pregnancies per 100 person-years in
South Africa (95% CI 2.60–4.18) to 21.68 per 100 person-years in
Rwanda (95% CI 17.10–27.50); the incidence of pregnancy was
between 6 and 9 per 100 person-years in each of the remaining
countries.
Figures 1 and 2 show the risk of pregnancy over time during the
pre-ART and on-ART periods, respectively. During the pre-ART
period the risk of pregnancy was lower and relatively constant,
peaking before 3 y of follow-up. In contrast, the risk of pregnancy
appeared to increase continuously with increasing duration of
follow-up in women on-ART, with pregnancy rates on-ART of
6.8, 9.9, 10.5, and 13.7 pregnancies per 100 woman-years of
observation during each of the first 4 y after ART initiation,
respectively (p,0.001).
Factors Associated with Incident Pregnancies
Table 2 shows the crude incidence of pregnancy during the pre-
ART and on-ART periods by women’s demographic and clinical
characteristics. Rates of pregnancy decreased sharply with
increasing age in all time periods; combining both the pre-ART
and on-ART periods, women ,25 y of age had more than double
the rate of new pregnancies compared to women $35 y. Higher
socioeconomic status (as reflected by education, employment,
access to electricity, and piped water) was associated with lower
rates of pregnancy, although the associations did not achieve
statistical significance in all intervals. Women who were married or
cohabiting at enrollment, and women who had male partners
enrolled into the program, also had significantly increased rates of
pregnancy. Primiparous women had similar pregnancy rates
compared to multiparous women and there was not a trend
towards lower pregnancy rates with increased parity. More
advanced WHO stage at enrollment was significantly associated
with decreased pregnancy rate during the pre-ART period but not
for women on-ART.
Women who reported any contraceptive use during follow-up
had lower pregnancy rates than those who did not. This
association was due largely to the effect of nonbarrier methods,
particularly injectable hormonal contraceptive use (unadjusted RR
during both the pre-ART and on-ART periods compared to no
contraceptive use, 0.18; 95% CI 0.13–0.24). Condom use was
associated with a higher pregnancy rate compared to nonbarrier
method use, but the rate was still lower than the rate among
women reporting no contraception. Overall, 89 pregnancies (15%)
occurred while women reported using a nonbarrier method, and
201 while women reported using condoms (34%).
Lower current CD4 counts during follow-up were associated
with lower pregnancy rates in both the pre-ART and on-ART
periods. Compared to women with current CD4 counts ,200
cells/ml, women with current CD4 counts $500 cells/ml had more
than five times the rate of pregnancy during the pre-ART period
(crude RR, 5.87; 95% CI 1.04–233.62); this association was
smaller but still significantly higher during the on-ART period
(crude RR, 1.92; 95% CI 1.36–2.70).
Multivariate Analysis
In a model examining pregnancy during the overall observation
period (combining pre-ART and on-ART periods) adjusted for
participant demographic and clinical characteristics, use of ART
was associated with an almost 80% increased risk of pregnancy
(HR, 1.74; 95% CI 1.19–2.54) (Table 3). In the same model, the
Figure 1. Instantaneous hazard of pregnancy during the pre-ART period by duration of follow-up, with 95% CIs.
doi:10.1371/journal.pmed.1000229.g001
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in the pre-ART group was less than 20%, compared to 33%
among women using ART (Figure 3). The association between
ART use and pregnancy persisted when the analysis was restricted
to women who initiated ART during follow-up (HR, 1.81; 95% CI
1.00–3.26). Other characteristics that were significantly associated
with an increased risk of pregnancy in the overall model included
younger age, lower levels of education, being married or
cohabiting, having a male partner enrolled into the program,
nonuse of nonbarrier forms of contraception, and higher current
CD4 cell counts. When the model was restricted to the pre-ART
and on-ART periods many of these associations persisted (Table 3).
In separate proportional hazards models including the overall
observation period stratified by country and adjusted for all
covariates shown in Table 3, the association between ART use and
incidence of pregnancy remained relatively constant across
countries although not all associations achieved statistical
significance. The weakest association was observed in Rwanda
(HR, 1.07; 95% CI 0.28–4.01), followed by Uganda (HR, 1.33;
95% CI 0.59–2.98), and Cote d’Ivoire (HR, 1.35; 95% CI 0.49–
3.70); stronger associations were observed at the sites in Kenya
(HR, 1.94; 95% CI 0.84–4.48), South Africa (HR, 2.33; 95% CI
0.70–7.73), and Zambia (HR, 2.82; 95% CI 0.80–9.97).
Discussion
The incidence of pregnancy among women enrolled in HIV
care and treatment programs in sub-Saharan Africa has important
implications for the health of women and their infants. Our
findings indicate a high overall incidence of pregnancy (more than
seven pregnancies per 100 woman-years of observation) and a
significant association between the use of ART and increased
incidence of pregnancy (adjusted HR, 1.74). Within 4 y of follow-
up, one-third of women who initiated ART experienced a
pregnancy, highlighting the urgent need to make pregnancy-
related services a central component of HIV care and ART
programs.
A series of biological and behavioral factors may influence the
association between the use of ART and increased incidence of
pregnancy. It is possible that the rapid improvements in health and
quality of life that take place with ART initiation lead to increased
sexual activity, particularly for those with stable partnerships [20].
Improving health with ART use may contribute to increased
fertility desires through psychological mechanisms of increased
hopefulness about the future and improved mental health, as well as
through increases in sexual activity and new partner acquisition
[21]. Related to this we found that more advanced HIV disease (as
indicated by higher WHO staging and lower CD4 cell counts) were
strongly associated with reduced incidence of pregnancy, consistent
with previous findings [22,23]. In addition it is important to note
that approximately 30% of pregnancies in sub-Saharan Africa are
unintentional [24,25], regardless of the HIV status of the mother,
and in this light other factors may also play a role. In particular, it is
plausible that improvements in immunological functioning with
ART increase female fecundity compared to pre-ART levels,
though the mechanisms through which ART use may reduce
pregnancy loss are not well understood.
We do not have data on sexual activity or fertility intentions to
help elucidate the reasons why ART use may increase fertility.
There is evidence that fertility intentions change over the natural
history of HIV infection. In keeping with the findings of qualitative
studies, a recent analysis of HIV-infected and -uninfected women
from Malawi [26] suggests that fertility intentions are diminished
by a diagnosis with HIV/AIDS and this may continue during the
Figure 2. Instantaneous hazard of pregnancy during the on-ART period by duration of follow-up, with 95% CIs.
doi:10.1371/journal.pmed.1000229.g002
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selected participant demographic, socioeconomic, clinical, and immunological characteristics.
Characteristics Incidence Rate (95% CI)
Overall Pre-ART On-ART
Overall 7.78 (7.18–8.43) 6.51 (5.74–7.38) 9.03 (8.13–10.04)
Baseline characteristics
Age (y)
,25 9.69 (8.43–11.12) 8.51 (7.04–10.29) 11.45 (9.36–14.00)
25–29 8.46 (7.42–9.63) 6.04 (4.84–7.53) 10.75 (9.15–12.63)
30–34 6.47 (5.44–7.70) 5.62 (4.25–7.44) 7.14 (5.72–8.91)
35+ 4.06 (2.90–5.69) (p,0.001) 3.15 (1.70–5.86) (p=0.001) 4.62 (3.10–6.90) (p,0.001)
Years of education (y)
0–3 13.75 (10.16–18.60) 13.60 (8.68–21.32) 13.86 (9.21–20.86)
4–7 9.27 (7.99–10.74) 7.98 (6.36–10.02) 10.49 (8.64–12.74)
8–11 7.16 (6.22–8.24) 5.77 (4.63–7.19) 8.58 (7.14–10.30)
12+ 5.20 (4.28–6.31) (p,0.001) 4.12 (3.02–5.62) (p,0.001) 6.25 (4.87–8.01) (p=0.002)
Currently employed
No 8.08 (7.37–8.85) 6.80 (5.91–7.83) 9.35 (8.29–10.54)
Yes 6.92 (5.81–8.24) (p=0.088) 5.60 (4.23–7.41) (p=0.166) 8.14 (6.51–10.18) (p=0.262)
Household electricity
No 9.09 (5.06–10.25) 7.82 (6.50–9.40) 10.34 (8.82–12.12)
Yes 6.98 (6.25–7.78) (p,0.001) 5.71 (4.81–6.78) (p=0.004) 8.21 (7.12–9.46) (p=0.017)
Household piped water
No 8.71 (7.86–9.65) 7.79 (6.68–9.09) 9.61 (8.37–11.02)
Yes 6.59 (5.77–7.51) (p,0.001) 4.91 (3.95–6.09) (p=0.001) 8.26 (6.99–9.75) (p=0.091)
Currently married/cohabiting
No 5.49 (4.65–6.47) 4.73 (3.68–6.08) 6.25 (5.02–7.78)
Yes 8.99 (8.18–9.87) (p,0.001) 7.41 (6.40–8.59) (p,0.001) 10.51 (9.31–11.86) (p=0.002)
Parity
Primiparous 7.62 (6.38–9.09) 5.66 (4.31–7.42) 10.21 (8.09–12.88)
Parity $2 7.85 (7.17–8.60) (p=0.774) 6.79 (5.89–7.82) (p=0.239) 8.80 (7.12–9.91) (p=0.269)
Travel time to facility (min)
,30 7.00 (6.08–8.07) 5.86 (4.73–7.26) 8.26 (6.83–9.98)
30–60 8.25 (7.36–9.24) 6.85 (5.73–8.19) 9.57 (8.26–11.09)
60+ 8.12 (6.67–9.88) (p=0.290) 7.15 (5.24–9.74) (p=0.462) 8.92 (6.93–11.49) (p=0.499)
WHO stage at enrollment
1 7.60 (6.85–8.42) 6.32 (5.46–7.31) 9.56 (8.25–11.08)
2 8.74 (7.41–10.30) 7.87 (5.98–10.36) 9.31 (7.58–11.43)
3 7.13 (5.72–8.89) 4.92 (2.79–8.66) 7.75 (6.10–9.85)
4 7.58 (4.08–14.09) (p=0.491) 0 (––) (p,0.001) 8.18 (4.40–15.20) (p=0.458)
CD4 at enrollment (cells/ml)
$500 8.21 (7.19–9.37) 7.34 (6.29–8.56) 12.39 (9.56–16.06)
350–499 7.52 (6.24–9.07) 5.88 (4.55–7.61) 10.91 (8.31–14.31)
20–349 7.23 (6.06–8.63) 4.32 (2.85–6.57) 8.47 (6.97–10.30)
,200 7.87 (6.66–9.31) (p=0.620) 4.09 (1.02–16.37) (0.113) 7.98 (6.74–9.45) (p=0.033)
Male partner enrolled
No 6.75 (6.10–7.46) 5.82 (5.00–6.76) 7.74 (6.76–8.85)
Yes 10.81 (9.44–12.38) (p,0.001) 8.88 (7.08–11.14) (p=0.005) 12.32 (10.39–14.60) (p,0.001)
Follow–up characteristics
Contraceptive use
None 14.38 (12.88–16.05) 13.12 (11.13–15.46) 15.61 (13.45–18.12)
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activity may increase after ART initiation, as suggested by a
cohort of Ugandan adults and a cross-sectional study from South
Africa [27,28]. Importantly, these and other studies [9,29] also
suggest that men are likely to express greater fertility desires than
women. In this study, we did not have data on male partners’
Characteristics Incidence Rate (95% CI)
Overall Pre-ART On-ART
Any barrier/nonbarrier method 5.08 (4.51–5.72) (p,0.001) 3.80 (3.12–4.61) (p,0.001) 6.34 (5.46–7.36) (p,0.001)
Condoms 7.33 (6.38–8.42) 5.70 (4.55–7.14) 8.89 (7.45–10.61)
Any nonbarrier method 2.59 (2.10–3.19) (p,0.001) 1.84 (1.30–2.60) (p,0.001) 3.36 (2.60–4.36) (p,0.001)
Injectable methods 1.53 (1.09–2.15) 1.10 (0.63–1.94) 1.97 (1.28–3.01)
Oral contraception 4.06 (2.56–6.44) 3.11 (1.55–6.21) 5.38 (2.89–10.00)
All hormonal methods 1.96 (1.49–2.58) 1.49 (0.96–2.30) 2.47 (1.74–3.51)
IUD use 0 0 0
Other
a 5.22 (3.81–7.14) 3.22 (1.83–5.67) 7.20 (4.94–10.50)
Most recent CD4 count (cells/ml)
$500 7.60 (6.64–8.69) 7.23 (6.10–8.55) 14.51 (11.59–18.17)
350–499 6.86 (5.84–8.06) 6.74 (5.37–8.45) 9.27 (7.37–11.66)
200–349 6.04 (5.11–7.14) 5.00 (3.53–7.07) 8.05 (6.65–9.75)
,200 5.71 (4.50–7.24) (p=0.069) 1.23 (0.17–8.74) (p=0.061) 7.56 (5.94–9.60) (p=0.002)




Table 3. Cox’s proportional hazards models examining the association between ART and incident pregnancy, presented as
adjusted HRs with 95% CIs.
Characteristics Overall (n=4,531) Pre–ART (n=3,951) On-ART (n=1,980)
HR 95% CI HR 95% CI HR 95% CI
On-ART (versus pre-ART) 1.74 1.19–2.54 — — — —
Age (continuous) 0.93 0.91–0.94 0.93 0.90–0.97 0.92 0.91–0.94
Years (y) of education
0–3 1.0 — 1.0 — 1.0 —
4–7 0.84 0.65–1.08 0.76 0.50–1.15 0.95 0.73–1.24
8–11 0.70 0.56–0.89 0.61 0.46–0.81 0.81 0.62–1.06
12+ 0.52 0.41–0.67 0.47 0.30–0.75 0.59 0.45–0.77
Married or cohabiting (versus not) 1.40 1.18–1.65 1.36 1.12–1.65 1.45 1.08–1.97
Parity $2 (versus primiparous) 1.17 0.96–1.44 1.37 0.90–2.08 1.02 0.72–1.45
Partner enrolled into program (versus not) 1.38 1.11–1.72 1.11 0.61–2.07 1.64 1.09–2.45
Use of nonbarrier contraception (versus
condoms only or no method)
0.31 0.19–0.50 0.22 0.12–0.41 0.42 0.24–0.72
Baseline WHO stage
1 — —1 . 0 —— —
2 — — 1.05 0.79–1.40 — —
3 & 4 — — 0.75 0.37–1.52 — —
Most recent CD4 count (cells/ml)
$500 1.0 — 1.0 — 1.0 —
350–499 0.83 0.67–1.02 0.87 0.70–1.07 0.73 0.51–1.05
200–349 0.68 0.44–1.05 0.58 0.44–0.77 0.68 0.35–1.33
,200 0.68 0.41–1.14 0.17 0.05–0.59 0.70 0.34–1.47
Each model is adjusted for all covariates listed.
doi:10.1371/journal.pmed.1000229.t003
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pregnancy in women who were married or cohabiting, as well as
those who had a male partner enrolled into the program, and most
male partners enrolled into the program were receiving ART.
These associations suggest the important role that partners are
likely to play in fertility among HIV-infected women, both in
shaping fertility-related decision making and providing an
opportunity to conceive [30].
Nonbarrier contraceptives, although used by only approximate-
ly one-fifth of women, were strongly associated with a reduced
incidence of pregnancy. This reduction was driven chiefly by use
of injectable hormonal contraceptives and the intrauterine device
(IUD), underscoring the valuable role of these methods for
pregnancy prevention. A substantial proportion of pregnancies in
this cohort occurred during self-reported method use, suggesting
that method failure, noncompliance, or over-reporting of method
use may occur in many instances. Among women reporting any
contraceptive method, the highest pregnancy incidence was
observed among those using condoms, highlighting the limited
effectiveness of condoms as a stand-alone contraceptive method
and emphasizing the importance of dual method use. The
association between oral contraceptive use and higher pregnancy
rates compared to other nonbarrier methods may reflect
nonadherence with oral contraceptive pills or drug interactions
between antiretroviral and oral contraceptive drugs [31]. There is
preliminary evidence that nevirapine through its inducer effect on
hepatic P450 enzymes is associated with decreased blood levels of
combined oral contraceptives [32].
The high incidence of pregnancy, coupled with the low
prevalence of contraceptive use, underscore the importance of
addressing fertility-related issues within HIV care and treatment
programs in sub-Saharan Africa. The increasing rate of new
pregnancies we observed with duration of follow-up on-ART is
consistent with findings from prior studies [27,28]. However, the
design and operation of most HIV treatment services do not
explicitly acknowledge the likelihood or the actual occurrence of
pregnancy [3]. Yet new pregnancies among HIV-infected women
enrolled in such programs have major implications for the clinical
management of the woman’s health in addition to requiring
attention for effective PMTCT [4]. HIV care and treatment
services must strengthen medical as well as psychosocial care to
address fertility desires and plans for both women and men with
HIV infection. For women who do not wish to become pregnant,
making effective methods of contraception as well as safe abortion
services available is critical. For women who desire a child,
appropriate planning prior to pregnancy, the choice of antiretro-
viral drugs, and the administration of effective PMTCT
interventions will optimize outcomes for both the mother and
child [16].
The data presented in this paper were derived from systematic,
standardized data collection in an HIV care and treatment
program across seven countries in sub-Saharan Africa. The
clinical sites that participated in this initiative are broadly
representative of public sector HIV care and ART delivery
programs, and thus the findings are likely to be more generalizable
than evidence from small research cohorts [10,33]. We observed
that the rates of incident pregnancy among HIV-infected women
range 5-fold across countries, which may reflect variation in
patient demographics and/or access to contraception and related
counseling. There was no specific package of fertility-related
Figure 3. Plot of the postestimation pregnancy-free survival function from a proportional hazards model for participants during
the pre-ART and on-ART periods. Model adjusted for participant age, education, nonbarrier contraceptive use, marital/cohabiting status, parity,
enrollment of partner into the program, and current CD4 count.
doi:10.1371/journal.pmed.1000229.g003
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Initiative, and site-specific heterogeneity in promotion of family
planning services may contribute to the observed differences.
Despite this, the association between ART use and pregnancy was
surprisingly consistent across countries; in a separate sensitivity
analysis (unpublished data), this association was minimally altered
by the removal of any single country from the analysis.
A distinctive strength of these data is that the analyses included
women followed up for incident pregnancies both before and after
ART initiation, as sites enrolled women into ongoing HIV care
regardless of disease stage or ART eligibility. However, our
findings should be interpreted in light of several limitations.
Although data were collected on standardized forms, the
ascertainment of new pregnancies was based on patient self-report
and clinical assessment rather than laboratory assays, a factor that
may have led to the underdetection of pregnancies. A proportion
of pregnancies are likely to be lost prior to clinical detection, which
may occur more frequently in HIV-infected women [34], making
these estimates of pregnancy incidence conservative. However, it is
unlikely that this ascertainment issue would have been influenced
by women’s use of ART. Similarly, imprecision in the clinical
dating of incident pregnancies and resultant inaccuracy in the
estimation of conception dates is also unlikely to have been
influenced by ART status (or other participant characteristics). It is
also important to note that this cohort was comprised of parous
women; although pregnancy rates are likely to be higher among
nulliparous women, it is unclear whether the impact of ART use
and other covariates would differ in women without children.
In summary, our findings indicate that the incidence of
pregnancy increases significantly after the initiation of ART.
Although the precise reasons for this increase require additional
research, HIV care and treatment programs have an important
opportunity to address women’s fertility intentions and to shape
their services to address the needs of the women and their families
over time.
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Background. Human immunodeficiency virus (HIV) causes
Acquired Immunodeficiency Syndrome (AIDS), which is a
major global cause of disease and death. More than 33
million people around the world are infected with HIV, with
nearly 5,500 dying daily from HIV and AIDS-related
complications. HIV/AIDS is especially problematic in sub-
Saharan Africa, where it is the leading cause of death. There
is no cure for HIV/AIDS, but medicines known as
‘‘antiretroviral therapy’’ (ART) can prolong life and reduce
complications in patients infected with HIV. 97% of patients
with HIV/AIDS live in low- and middle-income countries.
According to the World Health Organization, nearly 10
million of these patients need ART. As patients’ access to
treatment is often hindered by the high cost and low
availability of ART, global health efforts have focused on
promoting ART use in resource-limited nations. Such efforts
also increase awareness of how HIV is spread (contact with
blood or semen, in sexual intercourse, sharing needles, or
from mother to child during childbirth). ART reduces, but
does not remove, the chance of a mother’s passing HIV to
her child during birth.
Why Was This Study Done? By the end of 2007, 3 million
HIV-infected patients in poor countries were receiving ART.
Many of those treated with ART are young women of child-
bearing age. Childbirth is an important means of spreading
HIV in sub-Saharan Africa, where 60% of all HIV patients are
women. This study questions whether the improved health
and life expectancy that results from treatment with ART
affects pregnancy rates of HIV-infected patients. The study
explores this question in seven African countries, by
examining the rates of pregnancy in HIV-infected women
before and after they started ART.
What Did the Researchers Do and Find? The authors
looked at the records of 4,531 HIV-infected women enrolled
in the Mother-to-Child-Transmission-Plus (MTCT-Plus)
Initiative in seven African countries. MTCT -Plus, begun in
2002, is a family-centered treatment program that offers
regular checkups, blood tests, counseling, and ART
treatment (if appropriate) to women and their families. At
each checkup, women’s CD4+ cell counts and World Health
Organization guidelines were used to determine their
eligibility for starting ART. Over a 4-year period, nearly a
third of the women starting ART experienced a pregnancy:
244 pregnancies occurred in the ‘‘pre-ART’’ group (women
not receiving ART) compared to 345 pregnancies in the ‘‘on-
ART’’ group (women receiving ART). The chance of
pregnancy increased over time in the on-ART group to
almost 80% greater than the pre-ART group, while remaining
relatively low and constant in the pre-ART group. The
authors noted that, as expected, other factors also increased
the chances of pregnancy, including younger age, lower
educational status, and use of nonbarrier contraception such
as injectable hormones.
What Do These Findings Mean? This study suggests that
starting ART is associated with higher pregnancy rates in
sub-Saharan Africa, nearly doubling the chances of a woman
becoming pregnant. The reasons for this link are unclear.
One possible explanation is behavioral: women receiving
ART may feel more motivated to have children as their health
and quality of life improve. However, the study did not
examine how pregnancy desires and sexual activity of
women changed while on ART, and cannot discern why
ART is linked to increased pregnancy. By using pregnancy
data gathered from patient questionnaires rather than
laboratory tests, the study is limited by the possibility of
inaccurate patient reporting. Understanding how pregnancy
rates vary in HIV-infected women receiving ART helps
support the formation of responsive, effective HIV
programs. Female HIV patients of child-bearing age, who
form the majority of patients receiving ART in sub-Saharan
Africa, would benefit from programs that combine starting
HIV treatment with ART with education and contraception
counseling and pregnancy-related care.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000229.
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS, including a list of articles and other sources of
information about the primary care of adolescents with
HIV
N A UNAIDS 2008 report is available on the global AIDS
epidemic
N The International Planned Parenthood Foundation pro-
vides information on sexual and reproductive health and
HIV
N The International Center for AIDS Care and Treatment
Programs at the Columbia University Mailman School of
Public health provides information to assist HIV care and
treatment programs in resource-limited settings
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